_id
69105e90ccc777a4e85d592a
Ticker
DYN
Name
Dyne Therapeutics Inc
Exchange
NASDAQ
Address
1560 Trapelo Road, Waltham, MA, United States, 02451
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.dyne-tx.com
Description
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Last Close
19.42
Volume
2258428
Current Price
19.27
Change
-0.7723995880535639
Last Updated
2025-11-29T12:29:16.837Z
Image
-
Ipo Date
2020-09-17T00:00:00.000Z
Market Cap
3127860736
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.791
Sentiment Sources
4
Rating
4.4286
Target Price
35.375
Strong Buy
7
Buy
6
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
113892000
Operating Income
-113892000
Interest Expense
2904000
Pretax Income
-108041000
Net Income
-108041000
Eps
-0.7618667851023364
Dividends Per Share
-
Shares Outstanding
142824687
Income Tax Expense
-
EBITDA
-104614000
Operating Margin
-
Total Other Income Expense Net
5851000
Cash
573610000
Short Term Investments
218277000
Receivables
-
Inventories
-
Total Current Assets
806263000
Property Plant Equipment
45790000
Total Assets
867059000
Payables
12061000
Short Term Debt
5039000
Long Term Debt
99147000
Total Liabilities
175276000
Equity
691783000
Depreciation
500000
Change In Working Capital
5868000
Cash From Operations
-90779000
Capital Expenditures
19185000
Cash From Investing
-37965000
Cash From Financing
217327000
Net Change In Cash
88570000
PE
-
PB
3.9502209173541414
ROE
-15.617758748046715
ROA
-12.460628400143474
FCF
-109964000
Fcf Percent
-
Piotroski FScore
1
Health Score
38
Deep Value Investing Score
4
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
3
Net Net Investing Score
1
Quality Investing Score
3
Value Investing Score
3.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
113892000
Quarters > 0 > income Statement > operating Income
-113892000
Quarters > 0 > income Statement > interest Expense
2904000
Quarters > 0 > income Statement > pretax Income
-108041000
Quarters > 0 > income Statement > net Income
-108041000
Quarters > 0 > income Statement > eps
-0.7618667851023364
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
141810881
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-104614000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
5851000
Quarters > 0 > balance Sheet > cash
573610000
Quarters > 0 > balance Sheet > short Term Investments
218277000
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
806263000
Quarters > 0 > balance Sheet > property Plant Equipment
45790000
Quarters > 0 > balance Sheet > total Assets
867059000
Quarters > 0 > balance Sheet > payables
12061000
Quarters > 0 > balance Sheet > short Term Debt
5039000
Quarters > 0 > balance Sheet > long Term Debt
99147000
Quarters > 0 > balance Sheet > total Liabilities
175276000
Quarters > 0 > balance Sheet > equity
691783000
Quarters > 0 > cash Flow > net Income
-108041000
Quarters > 0 > cash Flow > depreciation
500000
Quarters > 0 > cash Flow > change In Working Capital
5868000
Quarters > 0 > cash Flow > cash From Operations
-90779000
Quarters > 0 > cash Flow > capital Expenditures
19185000
Quarters > 0 > cash Flow > cash From Investing
-37965000
Quarters > 0 > cash Flow > cash From Financing
217327000
Quarters > 0 > cash Flow > net Change In Cash
88570000
Quarters > 0 > ratios > PE
-0.7618667851023364
Quarters > 0 > ratios > PB
3.9502209173541414
Quarters > 0 > ratios > ROE
-15.617758748046715
Quarters > 0 > ratios > ROA
-12.460628400143474
Quarters > 0 > ratios > FCF
-109964000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
38
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
500000
Quarters > 1 > income Statement > gross Profit
-500000
Quarters > 1 > income Statement > operating Expenses
115791000
Quarters > 1 > income Statement > operating Income
-115791000
Quarters > 1 > income Statement > interest Expense
94000
Quarters > 1 > income Statement > pretax Income
-110857000
Quarters > 1 > income Statement > net Income
-110857000
Quarters > 1 > income Statement > eps
-0.9735143537098346
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
113873000
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-110260000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
4934000
Quarters > 1 > balance Sheet > cash
485040000
Quarters > 1 > balance Sheet > short Term Investments
198885000
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
697950000
Quarters > 1 > balance Sheet > property Plant Equipment
28534000
Quarters > 1 > balance Sheet > total Assets
728992000
Quarters > 1 > balance Sheet > payables
14016000
Quarters > 1 > balance Sheet > short Term Debt
5002000
Quarters > 1 > balance Sheet > long Term Debt
98813000
Quarters > 1 > balance Sheet > total Liabilities
157547000
Quarters > 1 > balance Sheet > equity
571445000
Quarters > 1 > cash Flow > net Income
-110858000
Quarters > 1 > cash Flow > depreciation
503000
Quarters > 1 > cash Flow > change In Working Capital
5641000
Quarters > 1 > cash Flow > cash From Operations
-94703000
Quarters > 1 > cash Flow > capital Expenditures
60000
Quarters > 1 > cash Flow > cash From Investing
6774000
Quarters > 1 > cash Flow > cash From Financing
100774000
Quarters > 1 > cash Flow > net Change In Cash
12845000
Quarters > 1 > ratios > PE
-0.9735143537098346
Quarters > 1 > ratios > PB
3.839971843309505
Quarters > 1 > ratios > ROE
-19.39941726675358
Quarters > 1 > ratios > ROA
-15.206888415785084
Quarters > 1 > ratios > FCF
-94763000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
38
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
502000
Quarters > 2 > income Statement > gross Profit
-502000
Quarters > 2 > income Statement > operating Expenses
122372000
Quarters > 2 > income Statement > operating Income
-122372000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-115361000
Quarters > 2 > income Statement > net Income
-115361000
Quarters > 2 > income Statement > eps
-1.0495760244559285
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
109912000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-121870000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
7011000
Quarters > 2 > balance Sheet > cash
472255000
Quarters > 2 > balance Sheet > short Term Investments
205237000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
689503000
Quarters > 2 > balance Sheet > property Plant Equipment
29629000
Quarters > 2 > balance Sheet > total Assets
721074000
Quarters > 2 > balance Sheet > payables
7019000
Quarters > 2 > balance Sheet > short Term Debt
5111000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
52101000
Quarters > 2 > balance Sheet > equity
668973000
Quarters > 2 > cash Flow > net Income
-115361000
Quarters > 2 > cash Flow > depreciation
502000
Quarters > 2 > cash Flow > change In Working Capital
-3602000
Quarters > 2 > cash Flow > cash From Operations
-105893000
Quarters > 2 > cash Flow > capital Expenditures
981000
Quarters > 2 > cash Flow > cash From Investing
1458000
Quarters > 2 > cash Flow > cash From Financing
141241000
Quarters > 2 > cash Flow > net Change In Cash
36806000
Quarters > 2 > ratios > PE
-1.0495760244559285
Quarters > 2 > ratios > PB
3.1660533982686894
Quarters > 2 > ratios > ROE
-17.244492677581906
Quarters > 2 > ratios > ROA
-15.998496686886504
Quarters > 2 > ratios > FCF
-106874000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
38
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
1572000
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
786000
Quarters > 3 > income Statement > operating Expenses
97108000
Quarters > 3 > income Statement > operating Income
-97108000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-89542000
Quarters > 3 > income Statement > net Income
-89542000
Quarters > 3 > income Statement > eps
-0.878017689396168
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
101982000
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-96658000
Quarters > 3 > income Statement > operating Margin
-6177.35368956743
Quarters > 3 > income Statement > total Other Income Expense Net
7566000
Quarters > 3 > balance Sheet > cash
435449000
Quarters > 3 > balance Sheet > short Term Investments
206819000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
659279000
Quarters > 3 > balance Sheet > property Plant Equipment
30013000
Quarters > 3 > balance Sheet > total Assets
691234000
Quarters > 3 > balance Sheet > payables
6562000
Quarters > 3 > balance Sheet > short Term Debt
4850000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
61396000
Quarters > 3 > balance Sheet > equity
629838000
Quarters > 3 > cash Flow > net Income
-89542000
Quarters > 3 > cash Flow > depreciation
1020000
Quarters > 3 > cash Flow > change In Working Capital
-5085000
Quarters > 3 > cash Flow > cash From Operations
-84335000
Quarters > 3 > cash Flow > capital Expenditures
1075000
Quarters > 3 > cash Flow > cash From Investing
-16010000
Quarters > 3 > cash Flow > cash From Financing
3636000
Quarters > 3 > cash Flow > net Change In Cash
-96714000
Quarters > 3 > ratios > PE
-0.878017689396168
Quarters > 3 > ratios > PB
3.12015651643756
Quarters > 3 > ratios > ROE
-14.21667158856722
Quarters > 3 > ratios > ROA
-12.953934557617247
Quarters > 3 > ratios > FCF
-85410000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-54.33206106870229
Quarters > 3 > health Score
30
Valuation > metrics > PE
-0.7618667851023364
Valuation > metrics > PB
3.9502209173541414
Valuation > final Score
40.49779082645858
Valuation > verdict
31.7% Overvalued
Profitability > metrics > ROE
-15.617758748046715
Profitability > metrics > ROA
-13.400218042995895
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.25336846959234327
Risk > metrics > Interest Coverage
-39.21900826446281
Risk > final Score
-97
Risk > verdict
High
Liquidity > metrics > Current Ratio
47.14988304093567
Liquidity > metrics > Quick Ratio
47.14988304093567
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
41.60028156690495
Prev Valuations > 1
48.33946601731311
Prev Valuations > 2
48.7984348356244
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
0
Prev Risks > 0
-4867
Prev Risks > 1
-15
Prev Risks > 2
5
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:24:35.193Z
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AEvercore Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $36 - 富途牛牛
12/15/2025
Evercore Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $36 富途牛牛
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$35.375
Analyst Picks
Strong Buy
7
Buy
6
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 81.09% of the total shares of Dyne Therapeutics Inc
1.
RA Capital Management, LLC(6.8284%)
since
2025/06/30
2.
HHG PLC(6.6341%)
since
2025/06/30
3.
BlackRock Inc(5.6785%)
since
2025/06/30
4.
Vanguard Group Inc(5.3781%)
since
2025/06/30
5.
FCPM III SERVICES BV(3.8399%)
since
2025/06/30
6.
FMR Inc(3.7208%)
since
2025/06/30
7.
Siren, L.L.C.(3.3996%)
since
2025/06/30
8.
Vanguard Total Stock Mkt Idx Inv(2.7442%)
since
2025/07/31
9.
TCG Crossover Management, LLC(2.6477%)
since
2025/06/30
10.
State Street Corp(2.3588%)
since
2025/06/30
11.
BRAIDWELL LP(2.3009%)
since
2025/06/30
12.
Adage Capital Partners Gp LLC(2.243%)
since
2025/06/30
13.
JPMorgan Chase & Co(2.1698%)
since
2025/06/30
14.
Armistice Capital, LLC(1.7995%)
since
2025/06/30
15.
Janus Henderson Glb Life Scn I2 USD(1.6862%)
since
2025/07/31
16.
T. Rowe Price Associates, Inc.(1.6757%)
since
2025/06/30
17.
iShares Russell 2000 ETF(1.5954%)
since
2025/08/31
18.
Geode Capital Management, LLC(1.5841%)
since
2025/06/30
19.
Perceptive Advisors LLC(1.5797%)
since
2025/06/30
20.
VR Adviser, LLC(1.5281%)
since
2025/06/30
21.
JPMorgan Small Cap Growth A(1.3654%)
since
2025/07/31
22.
Logos Global Management LP(1.3355%)
since
2025/06/30
23.
Janus Henderson Global Life Sciences(1.3267%)
since
2025/06/30
24.
Janus Henderson Global Life Sciences D(1.3267%)
since
2025/06/30
25.
Fidelity Growth Compy Commingled Pl S(1.2936%)
since
2025/07/31
26.
T. Rowe Price Investment Management,Inc.(1.2607%)
since
2025/06/30
27.
RTW INVESTMENTS, LLC(1.1883%)
since
2025/06/30
28.
Fidelity Select Biotechnology(1.1303%)
since
2025/07/31
29.
Janus Global Life Science AUSD(1.0925%)
since
2025/06/30
30.
Vanguard Small Cap Index(1.0587%)
since
2025/07/31
31.
SPDR® S&P Biotech ETF(0.9442%)
since
2025/08/31
32.
Fidelity Growth Company Fund(0.9084%)
since
2025/07/31
33.
T. Rowe Price Small-Cap Value(0.888%)
since
2025/07/31
34.
Vanguard Institutional Extnd Mkt Idx Tr(0.8535%)
since
2025/07/31
35.
US Small-Cap Growth II Equity Comp(0.7871%)
since
2025/06/30
36.
Vanguard Small Cap Value Index Inv(0.6835%)
since
2025/07/31
37.
Fidelity Small Cap Index(0.662%)
since
2025/06/30
38.
Biotech Growth Ord(0.6435%)
since
2025/05/31
39.
Janus Henderson Hrzn Biotec E2 USD(0.4748%)
since
2025/06/30
40.
T. Rowe Price New Horizons(0.4722%)
since
2025/07/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.